Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Maryland: - University of Maryland — Baltimore, Maryland
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Maryland: - The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine — Baltimore, Maryland
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed. Objective: To see if a study d…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05588141
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
NCT ID: NCT07416188
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK …
Sponsor: University of California, San Francisco
NCT ID: NCT04485559
Sites in Maryland: - John Hopkins University — Baltimore, Maryland
Phase 1 Recruiting Industry
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Sponsor: Boston Scientific Corporation
NCT ID: NCT05303467
Sites in Maryland: - Johns Hopkins Interventional Radiology Center — Baltimore, Maryland
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Maryland: - Advanced Molecular Imaging and Therapy — Glen Burnie, Maryland
- United Theranostics - Chesapeake — Glen Burnie, Maryland
Phase 1 Recruiting Industry
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DL…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT04541082
Sites in Maryland: - National Institutes of Health — Bethesda, Maryland
EARLY Phase 1 Recruiting Academic/Other
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutan…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06610682
Sites in Maryland: - Johns Hopkins — Baltimore, Maryland
Phase 1 Recruiting Academic/Other
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediat…
Sponsor: University of Maryland, Baltimore
NCT ID: NCT04772456
Sites in Maryland: - Rosy Njonkou Tchoquessi — Baltimore, Maryland
Phase 1 Recruiting NIH
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06344130
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Maryland: - Massive Bio SYNERGY-AI site — Baltimore, Maryland
- Massive Bio SYNERGY-AI site — Bethesda, Maryland
- Massive Bio SYNERGY-AI site — Silver Spring, Maryland
- Massive Bio SYNERGY-AI site — Towson, Maryland
NA Recruiting Industry
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS…
Sponsor: Monteris Medical
NCT ID: NCT05124912
Sites in Maryland: - University of Maryland — Baltimore, Maryland
NA Recruiting Academic/Other
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.
Sponsor: University of Maryland, Baltimore
NCT ID: NCT04699773
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
- UCH Kaufman Cancer Center — Bel Air, Maryland
- Central Maryland Radiation Oncology — Columbia, Maryland
- Baltimore Washington Medical Center — Glen Burnie, Maryland
Recruiting Academic/Other
The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07129317
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Recruiting NIH
Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2. Study Population A total of 269 partic…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
NCT ID: NCT00598351
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Recruiting NIH
Background: Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems. Researchers …
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
NCT ID: NCT02639325
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland